report-bg

Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Market Segmentation by Drug Type (Beta-Interferon, Cladribine, Dimethyl Fumarate, Fingolimod, Ozanimod, and Others); by Route of Administration (Oral, Injectable, and Intravenous) and by End-User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others) – Global Demand Analysis and Opportunity Outlook 2030

Buy Now Report ID: 3133 | Published Date: Feb 10, 2023

Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. Presently, the market in North America captures the larger share of the market, which is primarily attributed to the growing prevalence of RRMS in the region. According to the Multiple Sclerosis Association of America (MSAA), an estimated 1 million people in the United States are currently living with multiple sclerosis. In addition, it has been reported that the risk of developing multiple sclerosis in the U.S. is 3.5 in 1,000 people. Moreover, the favourable reimbursement policies in the country are also projected to drive the market’s growth in the forthcoming years. Another factor contributing to the growth of the market is the rising geriatric population in the region. According to the U.S. Census Bureau, more than 54 million people in the United States are aged 65 years and older. Moreover, it is to be noted that multiple sclerosis is becoming more prevalent in the geriatric population, which is further anticipated to generate a high demand for advanced treatment in the region.

Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Market

The global relapsing-remitting multiple sclerosis (RRMS) treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis


RN
Global Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Market
Get more information on this report: Request Free Sample PDF

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.


Market Segmentation

Market-Growth-Drivers

Our in-depth analysis of the global relapsing-remitting multiple sclerosis (RRMS) treatment market includes the following segments:

By Drug Type

  • Beta-interferon
  • Cladribine
  • Dimethyl Fumarate
  • Fingolimod
  • Ozanimod
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Intravenous

By End-user

  • Hospital
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Growth Drivers

  • Rising Prevalence of Relapsing-Remitting Multiple Sclerosis (RRMS)
  • Rapidly Increasing Geriatric Population

Challenges

  • High Cost of the Treatment


Healthcare Expenditure
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Market

top-features-companies
    • Biogen, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eisai Co., Ltd.
    • Glenmark Pharmaceuticals
    • Merck KGaA
    • Novartis AG
    • Sanofi-aventis Groupe
    • Teva Pharmaceutical Industries Ltd.
    • Genentech, Inc.
    • Acorda Therapeutics, Inc.
    • Amneal Pharmaceuticals LLC.

In-the-news

In The News

  • April 2021: Biogen announced that the European Commission had granted marketing authorization for its new subcutaneous administration of TYSABRI, which is indicated for the treatment of relapsing-remitting multiple sclerosis.
  • August 2020: Novartis AG announced that it has received FDA approval for its first and only self-administered targeted B-cell therapy, Kesimpta, which is used to treat patients with relapsing multiple sclerosis.

preview-analysis

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


Author Credits:  Radhika Gupta, Shivam Bhutani


Key Questions Answered in the Report

1) What are the major factors driving the growth of the relapsing-remitting multiple sclerosis (RRMS) treatment market?

Ans: The rising prevalence of relapsing-remitting multiple sclerosis and the rapidly growing aging population are the key factors driving the market growth.

2) What would be the CAGR of relapsing-remitting multiple sclerosis (RRMS) treatment market over the forecast period?

Ans: The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022-2030.

3) What are the challenges affecting the relapsing-remitting multiple sclerosis (RRMS) treatment market growth?

Ans: High cost of the treatment is one of the major factors estimated to hamper market growth.

4) Which region will provide more business opportunities for growth of relapsing-remitting multiple sclerosis (RRMS) treatment market in future?

Ans: The market in the Asia Pacific region will provide ample growth opportunities during the forecast period owing to the increasing prevalence of relapsing-remitting multiple sclerosis in countries, such as, China and India.

5) Who are the major players dominating the relapsing-remitting multiple sclerosis (RRMS) treatment market?

Ans: The major players dominating the relapsing-remitting multiple sclerosis (RRMS) treatment market are Biogen Inc., Eisai Co., Ltd., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Teva Pharmaceutical Industries Ltd., Genentech, Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company, which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the relapsing-remitting multiple sclerosis (RRMS) treatment market?

Ans: The market is segmented by drug type, route of administration, end-user, and region.

8) Which segment under the drug segment captures the largest market size in the relapsing-remitting multiple sclerosis (RRMS) treatment market?

Ans: With respect to the drug type, the beta-interferon segment is anticipated to grow at a lucrative rate over the forecast period owing to the growing number of drug approvals that are accelerating the market segment's growth.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy